Nanjing Pharmaceutical issued the second tranche of its 2026 medium-term notes in the national interbank market on July 9, with a total issuance amount of 500 million yuan, a term of three years, an interest accrual date of July 10, a maturity date of July 10, 2029, and an issuance rate of 1.68 percent. The bookrunner and lead underwriter is SPD Bank, and the joint lead underwriter is Bank of Hangzhou. The funds raised will be used to supplement working capital and repay bank loans.
NanJing Pharmaceutical Co LtdCompany issued 500M yuan medium-term notes at 1.68% to supplement working capital and repay loans; debt financing is neutral to slightly positive but not clearly beneficial or detrimental.